title: Inhibition by streptococcal immunopotentiator OK432 of lymph-node metastasis in hamster cheek-pouch carcinoma with enhancement of tumour necrosis factor-alpha and interleukin-6 in serum.
abstract: A well-known metastic model of human oral cancer employs 9,10-dimethyl-1,2-benzanthracene (DMBA) to induce hamster cheek-pouch carcinoma. Streptococcal immunopotentiator OK432 was studied here for its inhibitory effect on lymph-node metastasis in that model. The intraperitoneal administration of OK432, after excision of cheek-pouch tumours induced by DMBA, resulted in a marked reduction in the incidence of cervical lymph-node metastasis to 7%, a significant decrease beneath the rates observed for control animals not receiving OK432 (40%). OK432 also caused an increased in serum levels of tumour necrosis factor-alpha and interleukin-6 in tumor-bearing hamsters. These results suggest that the immune response may play an important part in the antimetastatic effects of OK432.
authors.affiliation: Department of Oral and Maxillofacial Surgery I, Matsumoto Dental College, Nagano, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Nakajima
authors.forename: M
authors.initials: M
authors.lastname: Mogi
authors.forename: T
authors.initials: T
authors.lastname: Chino
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene / Q000009:adverse effects; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002273:Carcinogens / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000517:prevention & control* / Q000556:secondary* / Q000601:surgery; D002610:Cheek / Q000473:pathology* / Q000601:surgery; D006224:Cricetinae; D004195:Disease Models, Animal; D006801:Humans; D007274:Injections, Intraperitoneal; D015850:Interleukin-6 / Q000097:blood* / Q000276:immunology; D008207:Lymphatic Metastasis / Q000517:prevention & control*; D008297:Male; D008647:Mesocricetus; D009062:Mouth Neoplasms / Q000473:pathology* / Q000601:surgery; D010844:Picibanil / Q000008:administration & dosage / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis* / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D002273:Carcinogens; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D010844:Picibanil; D015127:9,10-Dimethyl-1,2-benzanthracene